Bristol Myers Sqibb News (NYSE:BMY)

08/18/20176:59AMBWBristol-Myers Squibb & Pfizer to Highlight Commitment to Reducing the Risk of Stroke Caused by Non-Valvular Atrial Fibrillati...
Eliquis® (apixaban) Clinical Data Include Results from a Phase 4 Trial – EMANATE – to be Featured in Late-Breaking Science Sessions Analyses from the ACROPOLIS™ Global Real-World Data Program Provide Insight into the Anticoagulation of a Broad Range of NVAF Patients at Risk for Stroke Bristol-Myers Squibb Company... More...>>
08/15/20174:30PMBWBristol-Myers Squibb Announces Topline Results from CheckMate -214, a Phase 3 Study of Opdivo in Combination with Yervoy in I...
Co-Primary Endpoint of Objective Response Rate was met for the combination of Opdivo and Yervoy Co-Primary Endpoint of Progression-Free Survival Favored the combination of Opdivo and Yervoy vs. sunitinib but did not Reach Statistical Significance Bristol-Myers Squibb Company (NYSE: BMY) announced topline results today... More...>>
08/03/20174:00PMBWBristol-Myers Squibb to Acquire IFM Therapeutics to Strengthen Oncology Pipeline Focus on Innate Immunity
Gains full rights to IFM’s preclinical STING and NLRP3 agonist programs focused on enhancing the innate immune response for treating cancer Programs represent potentially differentiated approaches to initiate and augment immune responses in non-inflamed tumors IFM Therapeutics to receive $300 million upfront with potential... More...>>
08/01/20176:59AMBWBristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in MSI-H or dMMR Metastatic Colorectal Cancer That Has Prog...
Approval based on CheckMate -142, in which Opdivo demonstrated an objective response rate of 28% (95% CI: 17-42; 15/53) among patients who received prior treatment with a fluoropyrimidine, oxaliplatin, and irinotecan1,2 Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA... More...>>
07/31/20176:59AMBWBristol-Myers Squibb & Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) ...
Pivotal Phase 3 Trials Planned for 2017 will Evaluate Rubraca in Combination with Opdivo, Rubraca as Monotherapy, and Opdivo as Monotherapy in First Line Maintenance Treatment for Advanced Ovarian and Advanced Triple-Negative Breast Cancers Phase 2 Trial will Evaluate Opdivo in Combination with Rubraca and Other Compounds... More...>>
07/27/20176:59AMBWBristol-Myers Squibb Reports Second Quarter Financial Results
Increases Second Quarter Revenues 6% to $5.1 Billion Posts Second Quarter GAAP EPS of $0.56 and Non-GAAP EPS of $0.74 Achieves Important Clinical and Regulatory Milestones in Immuno-Oncology Opdivo Approved in Europe for Advanced Form of Bladder Cancer and Squamous Cell Carcinoma of the Head and Neck Opdivo Application... More...>>
07/27/20173:55AMDJNAstraZeneca Faces Major Setback Over Cancer Drugs
By Denise Roland AstraZeneca PLC said a combination of two of its new oncology drugs failed to shrink lung cancer tumors in a closely watched clinical trial, casting doubt on a central part of the company's ambitious growth plans. The trial, dubbed Mystic, centered on the combination of two immuno-oncology drugs... More...>>
07/26/20176:59AMBWBristol-Myers Squibb’s ORENCIA® (abatacept) Receives Second European Commission Approval in Less than a Year – New Appro...
Patients demonstrated improved disease response in two clinical trials that included both TNF-naïve and challenging to treat TNF-exposed patients with active musculoskeletal involvement1 Bristol-Myers Squibb Company (NYSE: BMY) announced today that the European Commission (EC) has approved ORENCIA alone or in combination... More...>>
07/24/20174:15PMBWU.S. Food & Drug Administration Accepts Bristol-Myers Squibb’s Applications for Opdivo (nivolumab) Four-Week Dosing Schedul...
Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) accepted its supplemental Biologics License Applications (sBLAs) to update Opdivo (nivolumab) dosing to include 480 mg infused over 30 minutes every four weeks (Q4W) for all currently approved monotherapy indications... More...>>
07/24/20176:59AMBWU.S. Food & Drug Administration Expands Approval of Yervoy® (ipilimumab) to Include Pediatric Patients 12 Years & Older with...
Yervoy showed a consistent safety profile and comparable drug levels across pediatric and adult patients First Bristol-Myers Squibb immuno-oncology approval for adolescents 12 years and older reflects the company’s commitment to the pediatric cancer community Bristol-Myers Squibb Company (NYSE:BMY) today announced that... More...>>
07/10/20178:00AMBWExelixis & Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in Combination with CABOMETYX™ or Opdivo & Yervoy® in C...
– First phase 3 trial in a global clinical development program to explore the combination of these agents – – Exelixis, Bristol-Myers Squibb and Ipsen to co-fund this trial – Exelixis, Inc. (NASDAQ:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the initiation of the phase 3 CheckMate 9ER trial... More...>>
07/10/20176:58AMBWU.S. Food & Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Sprycel (dasatinib) in C...
Submission includes powder for oral suspension formulation Application is based on results from Phase 2 CA180-226 study Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) to include an indication for Sprycel (dasatinib... More...>>
07/06/20177:30AMBWBristol-Myers Squibb’s ORENCIA (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis (PsA) in Adults
ORENCIA demonstrated symptom improvement in two randomized, double-blind, placebo-controlled trials that included adult PsA patients with active musculoskeletal symptoms ORENCIA now approved in three autoimmune diseases Bristol-Myers Squibb Company (NYSE:BMY) announced today the U.S. Food and Drug Administration (FDA... More...>>
07/05/20176:15AMBWPhase 3 Study Evaluating the Safety & Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary End...
Opdivo (nivolumab) demonstrates superior recurrence-free survival versus Yervoy (ipilimumab) in Adjuvant Setting in CheckMate -238 Bristol-Myers Squibb Company (NYSE:BMY) announced today that a Phase 3 study evaluating Opdivo 3 mg/kg versus Yervoy 10 mg/kg in patients with stage IIIb/c or stage IV melanoma who are at high... More...>>
06/28/20176:59AMBWModern Family Star Eric Stonestreet Challenges Americans to Support the Cancer Community & Learn about Immuno-Oncology Resear...
Dallas Cowboys quarterback Dak Prescott and actress/author Tia Mowry join Eric Stonestreet, Bristol-Myers Squibb and 30 cancer advocacy groups for the third year of the campaign Ready. Raise. Rise. is a social movement that empowers people to join the fight against cancer by supporting the cancer community, honoring loved... More...>>
06/24/201710:00AMBWFour-Year Follow-up with Empliciti (elotuzumab) Plus Lenalidomide/Dexamethasone (ELd) in Patients with Advanced Multiple Myel...
Combination therapy demonstrated a sustained reduction in risk of progression/death of 29% and relative improvement of 50% in progression-free survival rate of ELd (21%) compared to Ld alone (14%) The extended follow-up data is the longest of an Immuno-Oncology agent in relapsed/refractory multiple myeloma The data showed... More...>>
06/23/20177:29AMDJNOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a Cure
By Anne Steele The next frontier for multibillion-dollar drug therapies is a silent disease many people don't know they have. Dozens of pharmaceutical companies including Gilead Sciences Inc., Allergan PLC and Intercept Pharmaceuticals Inc. have joined the fray to bring a treatment for nonalcoholic steatohepatitis... More...>>
06/21/201710:00AMPRNUSS&P 500 Buybacks Fall 17.5% Year-over-Year to $133.1 Billion for Q1 2017
S&P 500 Buybacks Fall 17.5% Year-over-Year to $133.1 Billion for Q1 2017 - Q1 2017 repurchases is 1.6% less than Q4 2016 and 17.5% less than Q1 2016 - EPS support via share count reduction significantly declines - Cash reserves set new record PR Newswire NEW YORK, June 21, 2017 NEW YORK, June 21, 2017 /PRNewswire/... More...>>
06/21/20176:59AMBWBristol-Myers Squibb Announces the Expiration of its Cash Tender Offer
Bristol-Myers Squibb Company (NYSE:BMY) announced today the expiration, as of 5:00 p.m., New York City time, on June 20, 2017, of its previously announced cash tender offer for any and all of certain of its outstanding debt securities. Approximately $337.0 million in aggregate principal amount of the notes subject to the... More...>>
06/20/20173:40PMBWBristol-Myers Squibb Announces the Pricing Terms of its Cash Tender Offer For Any & All of Certain of its Outstanding Debt Se...
Bristol-Myers Squibb Company (NYSE:BMY) announced today the pricing terms of its previously announced cash tender offer for any and all of certain of its outstanding debt securities. The consideration for each series of notes is based on the applicable reference yield plus a fixed spread, in each case as set forth in the... More...>>
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V:us D:20170819 16:50:50